Xiang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiang Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hong Liu
Department of Dermatology, Xiangya Hospital Central South University, Changsha, Hunan, CHINA
2 shared publications Benliang Wei
Big Data Institute Central South University Changsha Hunan 410083 China
1 shared publicationDong Zhong
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
1 shared publicationJia Guo
Department of Dermatology, Xiangya Hospital Central South University Changsha Hunan 410008 China
1 shared publicationJinsong Ding
Xiangya School of Pharmaceutical Sciences Central South University Changsha Hunan 410013 China
1 shared publication- Juan Su
Department of Dermatology Xiangya Hospital, Central South University Changsha China
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102804
A purpurin-based metalloimmunostimulant amplifies ROS and modulates STING/TNF-α axis to potentiate melanoma immunotherapy
- 21 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102804
Open AccessA purpurin-based metalloimmunostimulant amplifies ROS and modulates STING/TNF-α axis to potentiate melanoma immunotherapy
- Open Access
- 24 December 2024
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2410545
Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity
Melanoma, a malignant skin tumor, presents significant treatment challenges, particularly in unresectable and metastatic cases. While immune checkpoint inhibitors (ICIs) targeting PD‐1/PD‐L1 have brought new hope, their efficacy is limited by low response rates and significant immune‐mediated adverse events (irAEs). Through multi‐omics data analysis, it is discovered that the spatial co‐localization of CD73 and PD‐L1 in melanoma correlates with improved progression‐free survival (PFS), suggesting a synergistic potential of their inhibitors. Building on these insights, a novel therapeutic strategy using calcium phosphate (CaP) nanoparticles is developed for the co‐delivery of aPD‐L1 and APCP, a CD73 inhibitor. These nanoparticles, constructed via a biomineralization method, exhibit high drug‐loading capacity and pH‐responsive drug release. Compared to free aPD‐L1, the CaP‐delivered aPD‐L1 effectively avoids systemic side effects while significantly enhancing anti‐tumor efficacy, surpassing even a 20‐fold dose of free aPD‐L1. Furthermore, the co‐delivery of aPD‐L1 and APCP via CaP nanoparticles demonstrates a synergistic anti‐tumor effect, with substantial immune activation and prevention of tumor recurrence through immune memory effects. These findings suggest that the co‐delivery of aPD‐L1 and APCP using CaP nanoparticles is a promising approach for improving melanoma immunotherapy, achieving enhanced efficacy and reduced toxicity.
- 24 December 2024
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2410545
Open AccessCo‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity
Melanoma, a malignant skin tumor, presents significant treatment challenges, particularly in unresectable and metastatic cases. While immune checkpoint inhibitors (ICIs) targeting PD‐1/PD‐L1 have brought new hope, their efficacy is limited by low response rates and significant immune‐mediated adverse events (irAEs). Through multi‐omics data analysis, it is discovered that the spatial co‐localization of CD73 and PD‐L1 in melanoma correlates with improved progression‐free survival (PFS), suggesting a synergistic potential of their inhibitors. Building on these insights, a novel therapeutic strategy using calcium phosphate (CaP) nanoparticles is developed for the co‐delivery of aPD‐L1 and APCP, a CD73 inhibitor. These nanoparticles, constructed via a biomineralization method, exhibit high drug‐loading capacity and pH‐responsive drug release. Compared to free aPD‐L1, the CaP‐delivered aPD‐L1 effectively avoids systemic side effects while significantly enhancing anti‐tumor efficacy, surpassing even a 20‐fold dose of free aPD‐L1. Furthermore, the co‐delivery of aPD‐L1 and APCP via CaP nanoparticles demonstrates a synergistic anti‐tumor effect, with substantial immune activation and prevention of tumor recurrence through immune memory effects. These findings suggest that the co‐delivery of aPD‐L1 and APCP using CaP nanoparticles is a promising approach for improving melanoma immunotherapy, achieving enhanced efficacy and reduced toxicity.